<DOC>
	<DOCNO>NCT01877226</DOCNO>
	<brief_summary>The purpose study evaluate pharmacokinetics ( explores body drug ) , safety tolerability single multiple-dose tapentadol healthy participant .</brief_summary>
	<brief_title>Phase 1 Pharmacokinetic Study Tapentadol Prolonged-Release 250 Milligram ( mg ) Formulation Healthy Participants</brief_title>
	<detailed_description>This open-label ( people know identity intervention ) , single-center , Phase 1 , single multiple-dose study tapentadol tamper resistant prolonged-release formulation ( TRF ) 250 milligram ( mg ) tablet healthy participant . The total study duration approximately 29 day per participant . The study consist 3 part : Screening ( , 21 day study commences Day 1 ) ; Treatment ( single-dose tapentadol Day 1 , multiple dose Day 4-6 [ follow washout period 24 hour ] ) ; End-of-study ( Day 8 ) . All eligible participant receive single oral dose tapentadol TRF 250 mg Day 1 twice daily Day 4-6 ( total 5 dos ) . Participants keep upright position 4 hour study drug administration . Study drug administer 30 minute breakfast morning . Blood sample collect evaluation pharmacokinetics pre-dose post-dose study treatment . Participants ' safety monitor throughout study .</detailed_description>
	<criteria>Deemed healthy basis prestudy physical examination , medical history , 12lead electrocardiogram ( ECG ) , vital sign , clinical laboratory parameter perform within 2 21 day first study drug administration Received thorough explanation optional pharmacogenomic research component study offer opportunity participate sign separate pharmacogenomic inform consent document Female participant must postmenopausal ( least 12 month since last menses ) , surgically sterile , , childbearing potential sexually active , practice effective method birth control entry throughout study Female participant must negative serum betahuman chorionic gonadotropin ( bhCG ) pregnancy test Screening Body mass index 20 28 kilogram per square meter ( kg/m^2 ) , inclusive , body weight less 50 kilogram Participants history seizure disorder epilepsy mild moderate traumatic brain injury , stroke , transient ischemic attack , brain neoplasm within 1 year Screening , severe traumatic brain injury History gastrointestinal disease affect absorption , gastric surgery history current significant medical illness include cardiac arrhythmia ( uneven heart beat ) cardiac disease , hematologic disease , coagulation disorder lipid abnormality , significant pulmonary disease , diabetes mellitus , renal hepatic insufficiency , thyroid disease , neurologic psychiatric ( mental disorder ) disease , infection , illness investigator considers exclude participant History clinically significant allergy , especially know hypersensitivity intolerance contraindication opioids , opioid antagonist , benzodiazepine , study drug formulation component , excipients formulation , heparin History , reason believe participant history lifetime opioid abuse , drug alcohol abuse within past 5 year Positive test drug abuse , cannabinoids , alcohol , opiates , cocaine , amphetamine , benzodiazepine , barbiturate Screening Day 1 first treatment period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Healthy</keyword>
	<keyword>Tapentadol</keyword>
</DOC>